Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Oncopeptides: Targeted oncology with commercial momentum - Edison

Oncopeptides

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved in Europe in 2022 for relapsed/refractory multiple myeloma (r/r MM) and is gaining traction across key geographies, notably Germany and Spain. The company reported net sales of SEK19.2m in Q225, a sizeable 135% increase year-on-year, reflecting the early impact of expanded commercial activities for the product. Current strategic priorities are focused on growing Pepaxti’s market presence (gearing up for commercialisation in Italy), advancing the development pipeline and achieving profitability by the end of 2026. Other key upcoming catalysts include potential partnerships in Japan for Pepaxti and further development of pipeline candidates such as OPD5.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.